share_log

三生国健(688336.SH):SSGJ-627注射液获得药物临床试验申请受理通知书

Sunshine Guojian Pharmaceutical (688336.SH): The SSGJ-627 injection has received the acceptance notification for the drug clinical trial application.

Gelonghui Finance ·  Jan 9 16:58

On January 9, Gelonghui reported that Sunshine Guojian Pharmaceutical (688336.SH) announced that it has received the "Acceptance Notice" approved by the National Medical Products Administration, indicating that the clinical trial application for SSGJ-627 injection (project code "SSGJ-627") has been accepted. SSGJ-627 injection is an innovative recombinant anti-TL1A humanized monoclonal antibody developed by Sunshine Guojian Pharmaceutical with independent intellectual property rights. TL1A (TNF Ligand-Related Molecule 1A) is a member of the tumor necrosis factor superfamily, primarily expressed by endothelial cells. It binds to DR3 (Death Receptor 3) to provide stimulating signals for downstream signaling pathways, regulating the proliferation, activation, apoptosis of effector cells, and the production of cytokines and chemokines. As a central regulatory factor in mucosal immune responses, allergies, and autoimmune conditions, TL1A/DR3 plays a critical role in autoimmune and autoinflammatory diseases, and inhibiting TL1A is an effective strategy in the treatment of autoimmune and inflammatory diseases.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment